Cita APA

Buske, C., Tedeschi, A., Trotman, J., García-Sanz, R., MacDonald, D., Leblond, V., . . . Arango-Hisijara, I. (2023). Plain Language Summary of the iNNOVATE study: Ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.

Citación estilo Chicago

Buske, Christian, et al. Plain Language Summary of the INNOVATE Study: Ibrutinib Plus Rituximab Is Well-tolerated and Effective in People With Waldenström's Macroglobulinemia. 2023.

Cita MLA

Buske, Christian, et al. Plain Language Summary of the INNOVATE Study: Ibrutinib Plus Rituximab Is Well-tolerated and Effective in People With Waldenström's Macroglobulinemia. 2023.